SCHEMBL7555201

SCHEMBL7555201

[CH2]CCCCCCCCCCCCCC(Br)CBr

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9147547 1.00 ALDH1A1 (0.33) ALDH1A1
SCHEMBL95808 0.89
SCHEMBL10352085 0.83 ALDH1A1 (0.44) ALDH1A1
SCHEMBL896257 0.78 ALDH1A1 (0.36) ALDH1A1
SCHEMBL2875490 0.77
SCHEMBL10600385 0.75 LCK (0.39)
SCHEMBL9584643 0.75 LCK (0.43)
SCHEMBL1976212 0.75
SCHEMBL2094998 0.75
SCHEMBL2090578 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020173489-A1 COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTER E.V. (DE) 2002-11-21 US disclosed
US-5916884-A CYTOTOXIC THERAPEUTIC COMPOUND; ANTITUMOR AGENT MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) 1999-06-29 US disclosed
EP-0916343-A1 use of alkzl phosphoric acid compounds for the treatment of psoriatic diseases ASTA Medica Aktiengesellschaft (DE) 1999-05-19 EP disclosed
US-5290769-A Applying compositions for skin disorders ASTA PHARMA AKTIENGESELLSCHAFT (DE) 1994-03-01 US disclosed
EP-0248062-B1 MEDICAMENTS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1992-05-06 EP disclosed
EP-0419998-A2 Use of alkylphosphonic acid derivatives for the treatment of psoriasis ASTA Medica Aktiengesellschaft (DE) 1991-04-03 EP disclosed
EP-0248858-B1 NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1990-02-28 EP disclosed
EP-0248858-A1 NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE. MAX PLANCK GESELLSCHAFT (DE) 1987-12-16 EP disclosed
WO-1987003596-A2 NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO disclosed
EP-0225608-A2 Medicine Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-06-16 EP disclosed
EP-0224925-A2 Phosphorous compounds and medicines containing them Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173489-A1 COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS PHOSPHO1, PLCG2, PPIP5K2 ALDH1A1 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.